AstraZeneca's Forxiga Gets EC Approval For Type-I Diabetes
Zacks Investment Research | Mar 24, 2019 10:10PM ET
AstraZeneca plc (NYSE:AZN) announced that the European Commission (EC) has approved a label expansion of its diabetes drug, Forxiga (dapagliflozin).
Forxiga has been approved for the treatment of type-1 diabetes (T1D) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2 when insulin alone does not provide adequate glycemic control despite optimal insulin therapy.
The approval was based on encouraging data from the phase III DEPICT study for Forxiga in T1D. Short-term (24 week) and long-term (52 week) data from DEPICT-1 along with short-term data from DEPICT-2 showed that Forxiga 5mg daily resulted in significant and clinically-meaningful reductions from baseline in average blood glucose levels HbA1c (primary endpoint), weight and total daily insulin dose (secondary endpoints) at 24 and 52 weeks.
We remind investors that Forxiga, a first-in-class, oral once-daily selective inhibitor of human sodium-glucose co-transporter 2 (SGLT2), is already approved as both monotherapy and combination therapy to improve glycemic control, with additional benefits of weight loss and blood pressure reduction, as an adjunct to diet and exercise in adults with type-2 diabetes (T2D).
In the past year, AstraZeneca’s shares have rallied 26.7%, outperforming the industry ’s growth of 17.2%.
Newer drugs like Brilinta (cardiovascular), Lynparza (ovarian cancer), Farxiga/Forxiga and Tagrisso (lung cancer) are driving top-line growth.
Sales of Forxiga came in at $1.3 billion in 2018. Label expansion of the drug will further boost the top line.
The drug is also under review in the United States and Japan for use as an adjunct treatment to insulin in adults with T1D. A decision in the United States is expected in the second half of 2019 and Japan in the first half.
We expect investors to now focus on the regulatory application in the United States. The FDA recently issued a complete response letter (“CRL”) to Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ’s new drug application (“NDA”) seeking approval of its lead pipeline candidate, Zynquista (sotagliflozin). Zynquista is a dual SGLT1 and SGLT2 inhibitor evaluated in combination with insulin for the treatment of T1D in adult patients. Lexicon is developing the candidate in collaboration with Sanofi (NASDAQ:SNY) .
Zacks Rank & A Key Pick
Get The News You Want
AstraZeneca currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Celgene Corporation (NASDAQ:CELG) .
Celgene’s earnings estimates have been revised 3.7% upward for 2019 over the past 60 days. The stock has rallied 37.5% so far this year.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.